Recent Finacing
Recent Raise
Akero Therapeutics is a biotechnology company developing AKR-001, a long-acting FGF21 analogue, to treat NASH and other metabolic diseases, advancing clinical development and manufacturing scale-up.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Akero Therapeutics.
